Officials from VaxGen, the maker of the experimental HIV vaccine AIDSVAX, on Monday released further details from the clinical trial data of AIDSVAX that offered no stronger proof of the company's claims that the vaccine offers significant protection against HIV infection for minorities, the San Francisco Chronicle reports. In late February, the company announced that while the vaccine was ineffective overall, lowering HIV infection risk by just 3.8% among all clinical trial participants, the vaccine did appear to offer protection in the range between 30% and 84% for Asians and African-Americans. But company officials on Monday said that efforts to account for the ethnic differences had been unsuccessful. Vice president Phillip Berman said the company expects an exhaustive analysis of the clinical trial data to take an additional six to 12 months.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes
These are some of his worst comments about LGBTQ+ people made by Charlie Kirk.